Tauns Laboratories, Inc. (JP:197A)
:197A
197A Stock Chart & Stats
¥509.00
¥4.00(0.67%)
At close: 4:00 PM EST
¥509.00
¥4.00(0.67%)
Day’s Range― - ―
52-Week Range¥418.00 - ¥618.00
Previous CloseN/A
Volume864.10K
Average Volume (3M)400.80K
Market Cap
¥56.30B
Enterprise Value¥74.20B
Total Cash (Recent Filing)¥9.27B
Total Debt (Recent Filing)¥14.42B
Price to Earnings (P/E)7.8
Beta0.48
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.09%
Share Statistics
EPS (TTM)N/A
Shares Outstanding106,433,120
10 Day Avg. Volume355,040
30 Day Avg. Volume400,796
Financial Highlights & Ratios
PEG Ratio1.16
Price to Book (P/B)3.14
Price to Sales (P/S)2.94
P/FCF Ratio25.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Profitability And MarginsSustained high gross and net margins and recent revenue growth indicate durable operating efficiency and pricing power in its specialty-medical niche. Strong margins support internal reinvestment, dividend capacity, and resilience to cyclical cost increases, bolstering long-term cash generation.
Solid Balance Sheet And High ROEA solid equity base and impressive ROE signal efficient capital allocation and financial resilience. Manageable leverage gives the company flexibility to fund targeted growth, withstand downturns, and maintain shareholder returns without immediately diluting or raising costly capital.
Improving Free Cash Flow GenerationMaterial improvement in free cash flow and a healthy operating-cash-to-income relationship point to better cash conversion and sustained internal funding for capex, R&D, or dividends. If maintained, stronger FCF reduces reliance on external financing and enhances strategic optionality.
Bears Say
Rising Total DebtAn upward trend in total debt, even from manageable levels, reduces financial flexibility and raises interest-cost sensitivity. If revenue or margins weaken, higher leverage could pressure cash flow, limit investment capacity, and force tighter capital allocation or refinancing at higher cost.
Historical Cash Flow VolatilityIntermittent negative operating cash flow and volatile free cash flow create unpredictability in funding cycles. Persistent volatility can force reliance on debt or equity funding, complicate long-term planning, and weaken the firm's ability to consistently fund dividends, capex, or strategic initiatives.
Slight Decline In Gross ProfitA drop in gross profit points to rising input costs or pricing pressure that, if sustained, could erode margins. Managing these cost pressures may require price increases, efficiency gains, or product mix shifts; failure to address them could compress long-term profitability.
Tauns Laboratories, Inc. News
197A FAQ
What was Tauns Laboratories, Inc.’s price range in the past 12 months?
Tauns Laboratories, Inc. lowest stock price was ¥418.00 and its highest was ¥618.00 in the past 12 months.
What is Tauns Laboratories, Inc.’s market cap?
Tauns Laboratories, Inc.’s market cap is ¥56.30B.
When is Tauns Laboratories, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tauns Laboratories, Inc.’s earnings last quarter?
Currently, no data Available
Is Tauns Laboratories, Inc. overvalued?
According to Wall Street analysts Tauns Laboratories, Inc.’s price is currently Overvalued.
Does Tauns Laboratories, Inc. pay dividends?
Tauns Laboratories, Inc. pays a Annually dividend of ¥14 which represents an annual dividend yield of 5.09%. See more information on Tauns Laboratories, Inc. dividends here
What is Tauns Laboratories, Inc.’s EPS estimate?
Tauns Laboratories, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tauns Laboratories, Inc. have?
Tauns Laboratories, Inc. has 106,433,120 shares outstanding.
What happened to Tauns Laboratories, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tauns Laboratories, Inc.?
Currently, no hedge funds are holding shares in JP:197A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tauns Laboratories, Inc.
TAUNS Laboratories, Inc. develops and manufactures vitro diagnostic drugs & measuring instruments. It also provides import and export of industrial measuring instruments, medical, physical, chemical and measuring instruments. The company was founded in April 1987 and is headquartered in Izunokuni, Japan.
Technical Analysis
Shin Nippon Biomedical Laboratories, Ltd.
―
Eiken Chemical Co., Ltd.
―
JCR Pharmaceuticals Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
Kitazato Corporation
―
Options Prices
Currently, No data available
---